U.S. FDA Approves LIVMARLI (maralixibat) as the First and Only Approved Medication for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome One Year of Age and OlderBusiness Wire • 09/29/21
Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in JapanBusiness Wire • 09/21/21
Mirum Pharmaceuticals Submits European Marketing Authorization Application for Maralixibat in Alagille Syndrome Supported by New Positive Results from Natural History Study ComparisonBusiness Wire • 09/13/21
Mirum Pharmaceuticals Appoints Biotechnology Executive William C. Fairey to its Board of DirectorsBusiness Wire • 08/19/21
Mirum Pharmaceuticals, Inc. (MIRM) CEO Chris Peetz on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/05/21
Mirum Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 08/05/21
Mirum Pharmaceuticals to Report Second Quarter 2021 Financial Results and Host Conference Call on August 5, 2021Business Wire • 07/29/21
Mirum Pharmaceuticals and GC Pharma Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Liver Diseases in South KoreaBusiness Wire • 07/27/21
Mirum Pharmaceuticals to Present at Piper Sandler's Virtual EASL Takeaway DayBusiness Wire • 06/24/21
Mirum Pharmaceuticals Presents Analyses From Its Rare Liver Disease Programs at the EASL International Liver Congress 2021Business Wire • 06/23/21
Mirum Pharmaceuticals to Showcase Analyses From Its Rare Liver Disease Programs at The International Liver Congress 2021Business Wire • 06/16/21
Mirum Pharmaceuticals Appoints Veteran Biotechnology Executive Carol L. Brosgart, M.D.Business Wire • 06/07/21
Mirum Pharmaceuticals Showcases Maralixibat Transplant-Free Survival Data for Progressive Familial Intrahepatic Cholestasis and Long-Term Safety Analyses for Alagille Syndrome during WCPGHAN Annual MeetingBusiness Wire • 06/03/21
Mirum Pharmaceuticals to Present Maralixibat Data and Host Symposium at the 6th World Congress of Pediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) Annual Meeting 2021Business Wire • 05/26/21
Mirum Pharmaceuticals' (MIRM) CEO Chris Peetz on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/09/21
Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/07/21
Mirum Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business UpdateBusiness Wire • 05/06/21
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million DealSeeking Alpha • 05/03/21
Mirum Pharmaceuticals to Report First Quarter 2021 Financial Results and Host Conference Call on May 6, 2021Business Wire • 04/29/21